Cargando…
Hepatitis C Virus NS3/4A Protease Inhibitors: A Light at the End of the Tunnel
Hepatitis C virus (HCV) infection is a serious and growing threat to human health. The current treatment provides limited efficacy and is poorly tolerated, highlighting the urgent medical need for novel therapeutics. The membrane-targeted NS3 protein in complex with the NS4A comprises a serine prote...
Autores principales: | Chatel-Chaix, Laurent, Baril, Martin, Lamarre, Daniel |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Molecular Diversity Preservation International (MDPI)
2010
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3185733/ https://www.ncbi.nlm.nih.gov/pubmed/21994705 http://dx.doi.org/10.3390/v2081752 |
Ejemplares similares
-
Very-long-chain fatty acid metabolic capacity of 17-beta-hydroxysteroid dehydrogenase type 12 (HSD17B12) promotes replication of hepatitis C virus and related flaviviruses
por: Mohamed, Bassim, et al.
Publicado: (2020) -
Allosteric Inhibitors of the NS3 Protease from the Hepatitis C Virus
por: Abian, Olga, et al.
Publicado: (2013) -
Variability and resistance mutations in the hepatitis C virus NS3 protease in patients not treated with protease inhibitors
por: Zeminian, Luciana Bonome, et al.
Publicado: (2013) -
Molecular models of NS3 protease variants of the Hepatitis C virus
por: da Silveira, Nelson JF, et al.
Publicado: (2005) -
The Molecular Basis of Drug Resistance against Hepatitis C Virus NS3/4A Protease Inhibitors
por: Romano, Keith P., et al.
Publicado: (2012)